

Immune Modulation Therapeutics

Targets, Technologies and Therapies

August 2008



Greystone
associates

Greystone Associates
98 Route 101A, Suite 17
Amherst, NH 03031
603-595-4340 • fax 603-804-0466

Drugs based on immune factors have the capability of interfering with disease-producing signaling processes at the molecular level

Drugs in this class currently represent a worldwide market of \$18 billions

More than three dozen companies are developing drug candidates based on this sophisticated approach to disease therapeutics

Pipeline drugs that will reach the market in the next four years will push the worldwide value of immune factor drugs to more than double current levels

Greystone Associates is pleased to announce the publication of a new market study. **Immune Modulation Therapeutics: Targets, Technologies and Therapies** is a comprehensive evaluation and analysis of recently approved drugs and development-stage candidates for treating chronic diseases, and an assessment of the therapeutic approaches and protocols and participants providing the driving force behind this growing segment of the healthcare sector.

Published in August (2008), the report has been designed and developed to provide pharmaceutical company decision makers, drug developers and formulators, and industry strategists with a detailed understanding of the expanding impact of an emerging generation of drugs on pharmaceutical strategies and healthcare treatment protocols for chronic diseases. Provider organization business managers, healthcare administrators and investors will also benefit from this publication.

Treating Disease by Modulating Signaling Activity

The recent impact of biological drugs in the treatment of serious illnesses has had a dramatic effect on therapeutic outcomes for previously refractory conditions and created needed commercial successes for pharmaceutical companies. These therapeutic treatments, which owe their clinical efficacy to their ability to stimulate or downregulate selected immune factors, have demonstrated the pervasive nature and medical potential of immune factors to developers, regulators and practitioners. Now a new generation of drug candidates that act by targeting one or more components of the immune cascade are winding their way through clinical development, most of them focused on treating chronic diseases.

Because these drugs and drug candidates target one or more receptors or mediators involved in immune cell signaling, many have been found capable of producing clinically meaningful benefit across a range of conditions. The therapeutic and market potential of immune factors in treating a broad spectrum of illnesses has attracted the attention of an increasing number of pharmaceutical companies. More than three dozen now have active development programs based on immune factor targets and mediators.

Table of Contents

Executive Summary

Immune Modulation in Disease Therapeutics

Evolving Models of Disease and Human Health
The Immune Response in Disease Incidence, Treatment & Prevention
The Immune Cascade
Receptors, Ligands and Cell Signaling Pathways

Immune Therapeutics – Commercial Realities

FDA-Approved Immune Factor Drugs
Patient and Disease Demographics
Competitive Landscape
Factors Limiting Growth
Regulatory Factors
Cost per Dose and Managed Care
Side Effects and Patient Compliance

Immune Modulation Therapeutics – Disease Sector Analysis

Autoimmune Diseases
Infectious Diseases
Hereditary Diseases
Oncology
Metabolic Diseases

Development-Stage Immune Factor Drug Candidates

Detailed Candidate Assessment, Status, and Commercial Prospects

TNF
Growth Factor inhibitors
Interleukins
Interferons
T-Cell Receptor Inhibitors
Innate Immune Cell Receptor Inhibitors
B-Cell Receptor Inhibitors
Kinase Inhibitors
Co-stimulator Inhibitors
Chemokine Receptors
Transcription Factors
Vascular Adhesion Inhibitors
Toll-like Receptors
Other Immune Factor Drug Candidates

Business Factors

Regulatory Factors
Clinical Trial Protocols & Endpoints
Alliances and Partnerships

Company Profiles

Market Data

The study presents qualitative and quantitative data and information on key market measures and benchmarks:

- Immune Drug Pipeline Analysis
- Therapeutic Sector Analysis
- Drug Technology Issues
- Economic Factors
- Demographic Demand Drivers
- Technology Risk Factors
- Industry Structure & Landscape
- Company Profiles
- Alliances and Strategies
- Product Status & Prospects
- Regulatory Factors
- Forecasts & Projections to 2011

Methodology

Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations.

Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations.

Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques

Feature Summary

- Analyzes and evaluates approved immune modulation drugs indicated for chronic diseases and assesses their market position and future prospects
- Assesses more than forty development-stage immune modulation drug candidates for chronic diseases, their therapeutic approach and commercial potential, and their market entry strategy and post-launch prospects
- Evaluates competing strategies, technologies and development issues
- Provides detailed analyses of chronic disease models for eleven major chronic illnesses and assesses pipeline candidate treatment strategies
- Forecasts commercial immune modulation drug activity and share data to 2011
- Profiles market sector companies, their product development activities, business strategies, and corporate alliances and affiliations
- Evaluates the impact of economic, technology, and regulatory factors on the commercialization of systemic therapeutics for chronic diseases

Report Format and Availability

This report is available in electronic format. A site license for a single physical location and a global license are also available. Publication is scheduled for August 2008, with availability on or before August 18th.

About Greystone Associates

Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis.

Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Ordering Information

Orders may be placed via postal mail, e-mail or fax. Orders not accompanied by a purchase order must contain a telephone number for verification, and clearly indicate the physical shipping address. Orders which are not prepaid must indicate the billing address. There is no charge for handling and shipping for destination addresses within the continental US.

Payment

We accept the following forms of payment:

Company Check: Please make checks payable to 'Greystone Associates'

Credit Cards: We accept MasterCard, Visa and American Express

Wire Transfers: See 'Wire Transfers' below for more information

Orders Outside the U.S.

Orders must be prepaid via credit card, company check in US funds and drawn on a US bank, or wire transfer. There is a \$50 per copy shipping and handling charge for international shipments.

Wire Transfers: Bank of New Hampshire
300 Franklin Street
Manchester, NH 03103
(Call for Account Information)

Mailing Address: P.O. Box 1362
Amherst, NH 03031

Immune Modulation Therapeutics: Targets, Technologies, and Therapies

Format	Price (U.S. funds)	Quantity	Total
Electronic	\$2,850.00		
Site License	\$3,850.00		
Global License	\$5,500.00		
Total Payment (U.S. funds)			

Method of Payment: Company Check    Wire Transfer (International)

Card Number: _____ Name on Card _____
Expiration Date: _____ Signature _____

Billing Information	Shipping Information
	<input type="checkbox"/> Click here if same as Billing Information
Name:	Name:
Title:	Title:
Company:	Company:
Street Address:	Street Address:
City,State/Province:	City,State/Province:
Country/Postal Code:	Country/Postal Code:
Phone:	Phone:
Fax:	Fax:
Email:	Email: